SpringWorks Therapeutics Has Initiated A Rolling Submission Of A New Drug Application To FDA For Mirdametinib In Pediatric And Adult Patients With Neurofibromatosis Type 1-associated Plexiform Neurofibromas; Expected To Complete By Q2 Of 2024
SpringWorks Therapeutics Has Initiated A Rolling Submission Of A New Drug Application To FDA For Mirdametinib In Pediatric And Adult Patients With Neurofibromatosis Type 1-associated Plexiform Neurofibromas; Expected To Complete By Q2 Of 2024
SpringWorks Therapeutics已開始向美國食品藥品管理局滾動提交米達替尼新藥申請,用於治療1型神經纖維瘤病相關叢狀神經纖維瘤的兒科和成人患者;預計將於2024年第二季度完成
SpringWorks Therapeutics Has Initiated A Rolling Submission Of A New Drug Application To FDA For Mirdametinib In Pediatric And Adult Patients With Neurofibromatosis Type 1-associated Plexiform Neurofibromas; Expected To Complete By Q2 Of 2024
SpringWorks Therapeutics已開始向美國食品藥品管理局滾動提交米達替尼新藥申請,用於治療1型神經纖維瘤病相關叢狀神經纖維瘤的兒科和成人患者;預計將於2024年第二季度完成